GIANNI BONADONNA, M. D.; PINUCCIA VALAGUSSA, B.S.; ARMANDO SANTORO, M.D.
In patients with stage IV Hodgkin's disease mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) was randomly tested against MOPP alternated monthly with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). All 88 evaluable patients had not received chemotherapy and 25 had had a relapse after primary irradiation. The complete remission rate with MOPP/ABVD was 88.9% (40 of 45 patients), and with MOPP, 74.4% (32 of 43 patients). The 8-year results show that MOPP/ABVD was superior to MOPP in terms of freedom from progression (64.6% compared to 35.9%; p < 0.005), relapse-free survival (72.6% compared to 45.1%; p < 0.01), total survival (83.9% compared to 63.9%; p < 0.06), and survival of complete responders (94.8% compared to 77.1%; p = 0.04). The delivery of MOPP/ABVD was not associated with an increased incidence of major toxicity. The early sequential rotation of two equally effective and non-cross-resistant drug combinations can substantially improve the likelihood of cure in patients with Hodgkin's disease.
BONADONNA G, VALAGUSSA P, SANTORO A. Alternating Non-Cross-Resistant Combination Chemotherapy or MOPP in Stage IV Hodgkin's Disease: A Report of 8-Year Results. Ann Intern Med. ;104:739–746. doi: 10.7326/0003-4819-104-6-739
Download citation file:
Published: Ann Intern Med. 1986;104(6):739-746.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use